Topic: Pharmaceuticals

CMA reaccuses Pfizer and Flynn of excessive pricing

The UK’s Competition and Markets Authority has accused Pfizer and Flynn Pharma of charging unfairly high prices for an anti-epilepsy medication, 17 months after an appellate court ordered the agency to redo parts of its initial probe into the drugmakers.

05 August 2021

FTC closes sham lawsuit case against AbbVie

The Federal Trade Commission has withdrawn its case against AbbVie after a Supreme Court ruling in April determined that the agency does not have the authority to seek restitution or disgorgement under Section 13(b) of the FTC Act.

02 August 2021

Portugal issues private health sector with SO over collective bargaining

The Portuguese Competition Authority has accused five hospitals and their business association of coordinating negotiation strategies to fix prices of services offered to public agencies, but lawyers have warned the case could mean “the end of collective bargaining” for professional organisations.

30 July 2021

CMA doles out £100 million in fines for excessive pricing of thyroid drug

The UK’s Competition and Markets Authority has hit Advanz Pharma and its two former owners with more than £100 million in fines for overcharging the country’s national health service for thyroid medication liothyronine over an eight-year period.

29 July 2021

Mylan secures victory in another EpiPen case

A federal Kansas judge has dismissed a pharmacy operator’s putative class action accusing Mylan and Pfizer of illegally monopolising the market for epinephrine auto-injectors used to treat severe allergic reactions.

28 July 2021

Takeda defeats sham litigation claims

Takeda Pharmaceuticals had a reasonable basis for alleging a generic drugmaker infringed upon its patented heartburn medication, a New Jersey federal court has said in finding the pharmaceutical company immune from allegations it illegally maintained a monopoly over Prevacid SoluTab.

28 July 2021

UK hits pharma companies with £266 million fines for overcharging health service

The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.

15 July 2021

Takeda and Endo hit with pay-for-delay claims

Takeda Pharmaceutical and Endo International are facing a lawsuit over an alleged scheme to block generic competition to Takeda’s branded anti-constipation drug Amitiza.

28 June 2021

Health authorities should have pushed alternative medication, Servier tells UK court

Servier has kicked off its bid to convince a UK court that national health authorities should have encouraged doctors to prescribe cheaper generic drugs to mitigate their losses from its pay-for-delay settlements relating to a blood pressure medication.

17 June 2021

Get unlimited access to all Global Competition Review content